[img]https://4.bp..com/-NVK9xTuUaug/WZctHqvXZMI/AAAAAAAAFAc/PO6I_8er1nQetkhyox_3yS-1QhkbTKqFgCKgBGAs/s1600/15030796006521250415730.jpg[/img]

Food and Drug Administration approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. ALL.

B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.

Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.

Women who are pregnant or breastfeeding should not take Besponsa because it may cause harm to a developing fetus or a newborn baby.

Side effects of Besponsa include low levels of platelets, low levels of certain white blood cells, infection, low levels of red blood cells, fatigue, severe bleeding, fever, nausea, headache, low levels of white blood cells with fever, liver damage, abdominal pain, high levels of bilirubin in the blood,
decrease in blood cell and platelet production, infusion-related reactions and problems with the heart’s electrical pulses.
[url]haleplushearty..com[/url]